Vifor Confident About Veltassa Despite AZ Rival

Hyperkalemia Therapy Now Has Competition From Lokelma

The Swiss company has been talking up its therapy for elevated levels of potassium in the blood which contributed to strong sales growth for Vifor in 2019.

Two_Road_Bikers
Vifor looks to maintain its lead over AstraZeneca in hyperkalemia market • Source: Shutterstock

Vifor Pharma Group is hopeful that its hyperkalemia therapy Veltassa, which enjoyed strong sales growth in 2019, will be able to fend off competition from AstraZeneca PLC's rival treatment Lokelma.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Blood and Clotting

In Brief: Bioxodes To Take Novel Hemorrhagic Stroke Drug Into Registrational Trial

 

The Belgium-based firm will take the first-in-class drug, based on tick saliva, targets inflammation without increasing bleeding, into a Phase IIb trial is in preparation, supported by a new series B funding round.

Sanofi Spends Big In US But Offers Crumbs Of Comfort For Europe

 
• By 

CFO François Roger tells Scrip the French drugmaker is flexible geographically on making investments but its spend in the US has risen regardless of the threat of tariffs.

Sanofi Set To Shake Up Crowded Hemophilia Space After Qfitlia Approval

 
• By 

The small interference RNA therapeutic can be used by patients regardless of inhibitor status.

With Phase III Success, PharmaEssentia To Seek Besremi Label Expansion (Update)

 
• By 

Taiwan-based PharmaEssentia hopes to add essential thrombocytopenia to the label for its pegylated interferon product, already approved to treat polycythemia vera.

More from Therapy Areas

GSK Chief Optimistic About BD Despite Volatile Environment

 
• By 

Emma Walmsley tells Scrip that the "biotech market is under a certain degree of pressure," so reasonably priced deals are available.

In Brief: AbbVie’s Rinvoq Secures US Approval For Giant Cell Arteritis

 

JAK inhibitor gains ninth indication in US after a strong performance in the first quarter.

CSPC’s Global-First Monospecific ADC Promising In Advanced NSCLC

 
• By 

CSPC’s SYS6010, the first monospecific EGFR-targeting antibody-drug conjugate in the clinic for advanced NSCLC, has shown Phase I promise, but could face close competition with another China-originated bispecific.